MX2022003401A - Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo. - Google Patents

Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo.

Info

Publication number
MX2022003401A
MX2022003401A MX2022003401A MX2022003401A MX2022003401A MX 2022003401 A MX2022003401 A MX 2022003401A MX 2022003401 A MX2022003401 A MX 2022003401A MX 2022003401 A MX2022003401 A MX 2022003401A MX 2022003401 A MX2022003401 A MX 2022003401A
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
compound
pyridone compound
fused
Prior art date
Application number
MX2022003401A
Other languages
English (en)
Inventor
Haibing Guo
Yang Liu
Jianbiao Peng
Jun Fan
Shuchun Guo
Fang Bao
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of MX2022003401A publication Critical patent/MX2022003401A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

En la presente invención se describe un compuesto de piridona fusionada, y un método de preparación para este y un uso de este. Específicamente, la presente invención describe un compuesto de la fórmula (I-B), un isómero óptico del mismo y una sal farmacéuticamente aceptable del mismo, y el uso del compuesto como un inhibidor de KRAS. (ver fórmula).
MX2022003401A 2019-09-20 2020-09-21 Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo. MX2022003401A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
CN201910892032 2019-09-20
CN201911129688 2019-11-18
CN201911157939 2019-11-22
CN202010054188 2020-01-17
CN202010102546 2020-02-19
CN202010230303 2020-03-27
CN202010306926 2020-04-17
CN202010367694 2020-04-30
CN202010967317 2020-09-15
PCT/CN2020/116510 WO2021052499A1 (zh) 2019-09-20 2020-09-21 稠合吡啶酮类化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
MX2022003401A true MX2022003401A (es) 2022-07-13

Family

ID=74883935

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003401A MX2022003401A (es) 2019-09-20 2020-09-21 Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo.

Country Status (14)

Country Link
US (1) US20220389029A1 (es)
EP (1) EP4043464A4 (es)
JP (1) JP2022549171A (es)
KR (1) KR20220086573A (es)
CN (2) CN114728968A (es)
AU (1) AU2020350745A1 (es)
BR (1) BR112022005193A2 (es)
CA (1) CA3155066A1 (es)
CL (1) CL2022000666A1 (es)
CO (1) CO2022004686A2 (es)
IL (1) IL291467A (es)
MX (1) MX2022003401A (es)
TW (1) TWI761961B (es)
WO (1) WO2021052499A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
EP4021444A4 (en) 2019-08-29 2023-01-04 Mirati Therapeutics, Inc. G12D KRAS INHIBITORS
CN114761012A (zh) 2019-09-24 2022-07-15 米拉蒂治疗股份有限公司 组合疗法
KR20220106980A (ko) 2019-10-28 2022-08-01 머크 샤프 앤드 돔 코포레이션 Kras g12c 돌연변이체의 소분자 억제제
EP4053118A4 (en) * 2019-10-30 2023-01-04 Genfleet Therapeutics (Shanghai) Inc. SUBSTITUTED HETEROCYCLIC CONDENSED CYCLIC COMPOUND, METHOD FOR PREPARATION AND PHARMACEUTICAL USE
IL294048A (en) 2019-12-20 2022-08-01 Mirati Therapeutics Inc sos1 inhibitors
EP4129997A4 (en) * 2020-04-03 2024-01-24 Medshine Discovery Inc OCTAHYDROPYRAZINODIAZANAPHTHYRIDINDIONE COMPOUNDS
US20230295163A1 (en) * 2020-08-21 2023-09-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Tetracyclic derivative, method for preparing same and use thereof in medicine
WO2022143995A1 (zh) * 2020-12-31 2022-07-07 正大天晴药业集团股份有限公司 四环类化合物及其医药用途
WO2022199669A1 (zh) * 2021-03-25 2022-09-29 上海济煜医药科技有限公司 稠合吡啶酮类化合物盐型、晶型及其应用
CN116848111A (zh) * 2021-03-26 2023-10-03 浙江海正药业股份有限公司 一种kras抑制剂关键中间体及其制备方法
CN115124533A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 四环类衍生物、其制备方法和其医药上的用途
CN116113632A (zh) * 2021-03-30 2023-05-12 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022223037A1 (zh) * 2021-04-22 2022-10-27 劲方医药科技(上海)有限公司 Kras抑制剂的盐或多晶型物
AU2022314009A1 (en) * 2021-07-23 2024-01-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
WO2023030517A1 (en) * 2021-09-06 2023-03-09 Suzhou Zanrong Pharma Limited Kras g12c inhibitors and uses thereof
TW202327593A (zh) * 2021-12-24 2023-07-16 大陸商勁方醫藥科技(上海)有限公司 Kras抑制劑的多晶型物及其製備方法和用途
CN116327956A (zh) * 2022-04-01 2023-06-27 劲方医药科技(上海)有限公司 药物组合物、其用途及癌症的治疗方法
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3055290B1 (en) * 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
MX2017012979A (es) * 2015-04-10 2017-11-28 Araxes Pharma Llc Compuestos de quinazolina sustituidos y metodos de uso de los mismos.
JP6789239B2 (ja) * 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
US9988357B2 (en) * 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US20200010479A1 (en) * 2017-02-03 2020-01-09 The University Of North Carolina At Chapel Hill Inhibitors of microbial beta-glucuronidase enzymes and uses thereof
CA3061650A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
TW201938561A (zh) * 2017-12-08 2019-10-01 瑞典商阿斯特捷利康公司 化學化合物
ES2969284T3 (es) * 2018-01-19 2024-05-17 Medshine Discovery Inc Derivado de piridona-pirimidina que actúa como inhibidor de la muteína krasg12c
JP7266043B2 (ja) * 2018-05-04 2023-04-27 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
KR20210121168A (ko) * 2019-01-29 2021-10-07 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. 복소환식 화합물인 벤조피리돈 및 그 사용
WO2020239123A1 (zh) * 2019-05-31 2020-12-03 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
CN112300194B (zh) * 2019-07-30 2022-01-14 上海凌达生物医药有限公司 一类稠环吡啶酮类化合物、制备方法和用途
EP4053118A4 (en) * 2019-10-30 2023-01-04 Genfleet Therapeutics (Shanghai) Inc. SUBSTITUTED HETEROCYCLIC CONDENSED CYCLIC COMPOUND, METHOD FOR PREPARATION AND PHARMACEUTICAL USE

Also Published As

Publication number Publication date
CA3155066A1 (en) 2021-03-25
IL291467A (en) 2022-05-01
JP2022549171A (ja) 2022-11-24
CN116947885A (zh) 2023-10-27
EP4043464A4 (en) 2023-10-04
EP4043464A1 (en) 2022-08-17
KR20220086573A (ko) 2022-06-23
TWI761961B (zh) 2022-04-21
CL2022000666A1 (es) 2022-10-14
WO2021052499A1 (zh) 2021-03-25
TW202126654A (zh) 2021-07-16
CN114728968A (zh) 2022-07-08
AU2020350745A1 (en) 2022-04-07
CO2022004686A2 (es) 2022-07-08
US20220389029A1 (en) 2022-12-08
BR112022005193A2 (pt) 2022-08-16

Similar Documents

Publication Publication Date Title
MX2022003401A (es) Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo.
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
ZA202208783B (en) Kras mutant protein inhibitors
AU2018271990A1 (en) Covalent inhibitors of KRAS
EP3878853A4 (en) NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, METHOD OF PREPARATION AND USE
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2022002831A (es) Compuestos heterociclicos.
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
SG11201810725WA (en) Novel β-lactamase inhibitors
MX2021007247A (es) Derivados de rapamicina.
WO2018039077A8 (en) Therapeutic compounds
PH12019550154A1 (en) Azetidine derivative
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
AU2017277002A1 (en) Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor
WO2021023888A8 (en) Quinoline derivatives as protein kinase inhibitors
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
CR20220255A (es) Inhibidores de egfr
MX2022006984A (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina.